



## **Paying for the Next Generation of Innovative Therapies**

**June 13, 2018**

Barbara Jordan Conference Center  
Kaiser Family Foundation  
1330 G Street, NW  
Washington, DC

**9:00 a.m. Welcome and Introductions**

Stuart Altman, Ph.D., Professor of National Health Policy, Brandeis University

**9:15 a.m. The Pharmaceutical Pipeline and Implications for Future Spending**

Scientific advances bring new therapies that may be more precisely targeted and more effective than current treatments, but that also carry higher prices. This session will review the current pipeline of new therapies, discuss cost implications and examine market and regulatory issues that could affect future spending on new drugs.

Speakers: Patrick Smith Pharm.D, Director, Clinical Pipeline Services, CVS Health  
Jonathan Darrow, S.J.D., LL.M, JD, MBA, Harvard Medical School  
Program on Regulation, Therapeutics and Law

**10:15 a.m. Should Launch Prices Be Based on the Value of New Therapies?**

A major concern with high drug prices is that when payers cannot negotiate effectively they may place restrictions on access leading to unmet patient needs. To address this issue, one approach would be developing arrangements where payers agree to reduce access barriers if drug prices are set based on independent assessments of cost-effectiveness. This session will examine mechanisms for implementing this type of value-based approach along with potential challenges of doing so.

Speakers: Sarah Emond, MPP, Chief Operating Officer, ICER  
Colleen Rye, Ph.D, Director, FasterCures  
Jason Spangler MD, Executive Director of Value, Quality, & Medical  
Policy, Amgen

**11.30 a.m. Break**

**11:45 a.m. Outcome-Based Contracting Models for High-Cost Therapies**

Payers and pharmaceutical firms have increasingly entered into “value-based” or “outcome-based” arrangements where the price of therapies are adjusted based on treatment outcomes. This session will discuss the nature of existing arrangements that focus on both population and individual patient outcomes, provide an assessment of how well programs have been working, and identify future opportunities and challenges.

Speakers: Dan Leonard MA, President, National Pharmaceutical Council  
Michael Sherman MD, Chief Medical Officer, Harvard Pilgrim Healthcare  
Anna Kaltenboeck MA, Program Director, Drug Pricing Lab at Memorial Sloan Kettering

**1:00 p.m. Lunch Served**

**1:15 p.m. Mortgages for Medical Care? Paying for Cost-Effective Therapies with High Up-Front Costs**

The FDA has recently approved new treatments that are highly effective and potentially curative but with very high launch prices. Even if they are cost effective, therapies with very high up-front costs and substantial long-term benefits pose a challenge to the current model of health insurance. Some have suggested models that spread the cost of such therapies broadly across the insurance pool. This session will discuss the opportunities and challenges of potential new financing approaches.

Speakers: Steven Miller MD, MBA. Chief Medical Officer, Express Scripts  
Kristin Viswanathan Wolff, Director, Global Government Affairs and Public Policy, bluebird bio

**2:30 p.m. Meeting adjourns**